MAP2K7 and neoplasm: Indeed, we observed that, particularly in the case of the MEK inhibitor trametinib, knockdown of NF1 in cell lines either wildtype for or with het-loss of this gene resulted in a shift in the sensitivity phenotype toward that of the tumor cells with complete ablation.